FDA Grants Lannett (LCI) Approval for Hydrochlorothiazide Capsules, 12.5 mg

Lannett Company, Inc. (NYSE: LCI) today announced it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Hydrochlorothiazide Capsules, 12.5 mg. Hydrochlorothiazide Capsules, 12.5 mg, is therapeutically equivalent to the reference listed drug, Microzide Capsules, 12.5 mg, of Watson Pharmaceuticals. Sales of Hydrochlorothiazide Capsules, 12.5 mg, at Average Wholesale Price were approximately $204 million for the 12 months ending October 2011, according to Wolters Kluwer. Shipping is expected to commence shortly.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Creative Medical completes enrollment in ADAPT back pain trial
• Blue Star Gold reports phase 2 drilling results at Nutaaq target